Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Jul
15
Today In Oncology
Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer
FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors
American Cancer Society Reports Latest Global Cancer Statistics
Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors
Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo